Abstract: The present invention relates to techniques and methods for producing, purifying, inactivating and analyzing SARS-CoV-2. The present invention relates to the method for producing an antigen corresponding to the SARS-COV-2 virus inactivated by gamma radiation. The method for producing an antigen corresponding to the SARS-COV-2 virus inactivated by gamma radiation is intended for use in the production of a novel vaccine, the antigen being used in the production of hyperimmune plasma in horses for serum therapy, and in different animal species for the production of antibodies/research inputs and the establishment of serum diagnosis techniques. The present invention relates to the antigenic composition including the antigen corresponding to the inactivated SARS-COV-2 virus and a pharmaceutically acceptable diluent excipient. The invention also relates to a method for producing anti-SARS-CoV-2 immunoglobulins using the SARS-COV-2 virus inactivated by gamma radiation.

Abstract: A class of proteins that inhibit thrombin, particularly direct inhibitor of thrombin modified from sculptin, identified in the transcriptomics analysis of the salivary glands of ticks, as well as fragments and recombinant protein thereof, which can be used as anticoagulant agents and for the prophylaxis and/or treatment of thromboembolic diseases. These proteins fall within the fields of biochemistry, molecular biology, genetics, pharmacy and medicinal chemistry, being related to biochemical and metabolic processes.

Abstract: The invention falls within the fields of pharmaceutical sciences, immunology and methods of treatment of cancer Methods. More specifically, the invention relates to a compound for modulating one or more innate immune pathways selected from RLR, TLR, OAS and/or oncostatin M, said compound being amblyomin-×or peptides derived from amblyomin-X. Use of said compound for preparing medicines; a pharmaceutical composition comprising said compound, a method for modulating said pathways in vitro and a method of treatment are also described.

Abstract: Various sequences of new peptides and derivatives with anti-inflammatory effects in various cellular models (chondrocytes osteoclasts, macrophages derived from THP-1, and neurons) in the context of stimulus-induced inflammation widely known in the literature for each model. The compounds were shown to be able to reverse the expression of molecules associated with the cell's inflammatory mechanism, in addition to inducing regenerative proteins and reducing pain markers. Accordingly, the claimed compounds of the present invention can be applied to degenerative diseases of an inflammatory nature including rheumatoid arthritis and osteoarthritis.

Abstract: The invention pertains to the technical fields of pharmaceutical sciences, immunology, diagnosis and/or treatment of cancer. Specifically, the invention relates to peptides derived from the C-terminal portion of the tick amblyomin-X protein, said peptides being intended for targeting or promoting the internalization of molecular entities into the intracellular domain of eukaryotic or neoplastic cells. The invention also relates to the use of said peptides for modifying other pharmaceutically active ingredients, to a pharmaceutical composition comprising said peptides and to a method of diagnosis, prognosis and/or treatment of cancer or other cell-altering conditions.

Abstract: The present invention relates to novel hybrid peptides developed from the combination of membrane surface protein peptide fragments present in anaplasmosis microorganisms, and in particular, bacteria of the species Anaplasma marginale. The present invention further relates to hybrid peptide sets, compositions and kits comprising such novel hybrid peptides, their uses and methods of inducing immune response. Each hybrid peptide, according to the present invention, comprises two or more peptide fragments of amino acid sequences as defined in the present invention linked together by means of a spacer element. The combined peptide fragments are protein peptide fragments of MSP1, MSP1a, MSP1b, MSP2, MSP2-HRV, MSP3, OMP7, OMP8, VirB9 and VirB10.

Abstract: The present invention relates to novel hybrid peptides developed from the combination of membrane surface protein peptide fragments present in anaplasmosis microorganisms, and in particular, bacteria of the species Anaplasma marginale. The present invention further relates to hybrid peptide sets, compositions and kits comprising such novel hybrid peptides, their uses and methods of inducing immune response. Each hybrid peptide, according to the present invention, comprises two or more peptide fragments of amino acid sequences as defined in the present invention linked together by means of a spacer element. The combined peptide fragments are protein peptide fragments of MSP1, MSP1a, MSP1b, MSP2, MSP2-HRV, MSP3, OMP7, OMP8, VirB9 and VirB10.

Abstract: Compositions for regenerating tissue and wound repair, among other applications, are described.

Abstract: The invention refers to pharmaceutical compositions and cosmetic compositions comprising a prophylactic or therapeutically effective quantity of at least one polypeptide substantially identical to Lopap (a lipocalin-related protein with prothrombin activating protease activity). The invention refers to the use of these compositions as modulators of cell death and anti-aging agents.

Abstract: The present invention presents a Kunitz-type recombinant inhibitor obtained from a gene cloned from a cDNA library of salivary glands of the Amblyomma cajennense, and the inhibitor named Amblyomin-X has molecular mass of 13,500 Da.

Abstract: Compositions for regenerating tissue and wound repair, among other applications, are described.

Abstract: The invention refers to pharmaceutical compositions and cosmetic compositions comprising a prophylactic or therapeutically effective quantity of at least one polypeptide substantially identical to Lopap (a lipocalin-related protein with prothrombin activating protease activity). The invention refers to the use of these compositions as modulators of cell death and anti-aging agents.

Abstract: The present invention presents a Kunitz-type recombinant inhibitor obtained from a gene cloned from a cDNA library of salivary glands of the Amblyomma cajennense, and the inhibitor named Amblyomin-X has molecular mass of 13,500 Da.

Abstract: This invention refers to the process for obtaining the recombinant prothrombin activating protease (rLopap) in monomeric form, the recombinant prothrombin activating protease (rLopap), as well as its amino acid sequence. In addition to that, this invention also refers to the use of this protease for depleting the blood fibrinogen, and serve as diagnosis kit for dysprothrombinemias. This invention describes the obtainence in recombinant form and the characterization of a prothrombin activator protease of 21 kDa, named rLopap (Lonomia obliqua prothrombin activator protease), with serineproteases characteristics however it shows sequence of conserved amino acids as in a lipocalin family. The protein presents pro-coagulating activity, depleting blood fibrinogen and prolonging the coagulation time of human blood/plasma. The obtainence of rLopap in its recombinant form and showing adequate activity for allowing clinical Pharmacology essays is presented in this invention.